SG11202107762QA - Aflibercept attributes and methods of characterizing and modifying thereof - Google Patents

Aflibercept attributes and methods of characterizing and modifying thereof

Info

Publication number
SG11202107762QA
SG11202107762QA SG11202107762QA SG11202107762QA SG11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA SG 11202107762Q A SG11202107762Q A SG 11202107762QA
Authority
SG
Singapore
Prior art keywords
aflibercept
characterizing
attributes
modifying
methods
Prior art date
Application number
SG11202107762QA
Other languages
English (en)
Inventor
Quanzhou Luo
Diana Woehle
Matthew Jerums
Scott Kuhns
Xuejun Han
Kelli M G Matthies
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202107762QA publication Critical patent/SG11202107762QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202107762QA 2019-01-30 2020-01-29 Aflibercept attributes and methods of characterizing and modifying thereof SG11202107762QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962798903P 2019-01-30 2019-01-30
PCT/US2020/015659 WO2020160133A1 (en) 2019-01-30 2020-01-29 Aflibercept attributes and methods of characterizing and modifying thereof

Publications (1)

Publication Number Publication Date
SG11202107762QA true SG11202107762QA (en) 2021-08-30

Family

ID=69726812

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107762QA SG11202107762QA (en) 2019-01-30 2020-01-29 Aflibercept attributes and methods of characterizing and modifying thereof

Country Status (8)

Country Link
US (1) US20220098279A1 (ja)
EP (1) EP3917951A1 (ja)
JP (1) JP2022523063A (ja)
AU (1) AU2020216368A1 (ja)
CA (1) CA3127228A1 (ja)
MX (1) MX2021008983A (ja)
SG (1) SG11202107762QA (ja)
WO (1) WO2020160133A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112739323A (zh) 2018-05-10 2021-04-30 瑞泽恩制药公司 含有高浓度vegf受体融合蛋白的制剂
TW202128744A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
RU2642664C2 (ru) * 2011-11-18 2018-01-25 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
EP2879694A1 (en) * 2012-08-02 2015-06-10 Sanofi Article of manufacture comprising aflibercept or ziv-aflibercept
CN105636986B (zh) * 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
WO2016089919A1 (en) * 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질

Also Published As

Publication number Publication date
CA3127228A1 (en) 2020-08-06
MX2021008983A (es) 2021-09-08
AU2020216368A1 (en) 2021-08-12
US20220098279A1 (en) 2022-03-31
EP3917951A1 (en) 2021-12-08
WO2020160133A1 (en) 2020-08-06
JP2022523063A (ja) 2022-04-21

Similar Documents

Publication Publication Date Title
IL276731A (en) Antibodies against CD73 and methods of using them
IL279965A (en) Unified structures and methods for their use
IL278821A (en) Anti-SIRPA antibodies and methods of using them
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
EP3645742A4 (en) ANTI-ROR1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of using them
IL290741A (en) Antibodies against cd-96 and methods of using them
EP3675906A4 (en) ANTI-TM4SF1 ANTIBODIES AND METHOD OF USING THEREOF
IL276285A (en) Activated antibodies and methods of making and using them
SG11202108734VA (en) Anti-trem2 antibodies and methods of use thereof
IL279648A (en) Anti-SIRP-in-cell 1 antibodies and methods of using them
IL287282A (en) Anti-mertk antibodies and methods of using them
IL277212A (en) Anti-KLK5 antibodies and methods of use
IL288091A (en) Methods for characterizing and using condensed matter-matter interactions
IL289829A (en) Antibodies for modulating the immune system and methods of using them
IL289952A (en) Anti-ms4a4a antibodies and methods of using them
IL285117A (en) Methods for characterizing properties related to condensation of compounds and their uses
IL285401A (en) Anti-clec2d antibodies and methods of using them
IL283884A (en) Antibodies against il-36 and methods of using them
IL291461A (en) Anti-alpha-synuclein antibodies and methods of using them
IL280338A (en) Anti-SIGLEC-5 antibodies and methods of using them
SG11202107762QA (en) Aflibercept attributes and methods of characterizing and modifying thereof
IL288886A (en) Antibodies and methods of use
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same